BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15905710)

  • 21. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesalamine maintenance therapy for Crohn's disease.
    Feagan BG; McDonald JW
    Gastroenterology; 2001 Feb; 120(2):585-6. PubMed ID: 11271451
    [No Abstract]   [Full Text] [Related]  

  • 23. Increased levels of circulating platelet derived microparticles in Crohn's disease patients.
    Tziatzios G; Polymeros D; Spathis A; Triantafyllou M; Gkolfakis P; Karakitsos P; Dimitriadis G; Triantafyllou K
    Scand J Gastroenterol; 2016 Oct; 51(10):1184-92. PubMed ID: 27191369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesalamine and relapse prevention in Crohn's disease.
    Cottone M; Cammà C
    Gastroenterology; 2000 Aug; 119(2):597. PubMed ID: 10960274
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mesalazine is effective in Crohn disease 2].
    Quartarolo JP; Laegemidler F; Eskerod O
    Ugeskr Laeger; 2005 Mar; 167(11):1308-9; author reply 1309. PubMed ID: 15830510
    [No Abstract]   [Full Text] [Related]  

  • 26. [Mesalazine is effective in Crohn disease 1].
    Fallingborg J; Langholz E; Christensen LA; Munkholm P; Dahlerup JF
    Ugeskr Laeger; 2005 Mar; 167(11):1307-8; author reply 1309. PubMed ID: 15830509
    [No Abstract]   [Full Text] [Related]  

  • 27. Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease.
    Rutgeerts P
    Gut; 2001 Apr; 48(4):452-3. PubMed ID: 11247886
    [No Abstract]   [Full Text] [Related]  

  • 28. [Improved treatment of Crohn's disease].
    Nau JY
    Rev Med Suisse; 2005 May; 1(18):1241. PubMed ID: 15977716
    [No Abstract]   [Full Text] [Related]  

  • 29. Current treatment for prevention of relapse and recurrence in Crohn's disease.
    Prantera C; Scribano ML
    Ital J Gastroenterol Hepatol; 1999; 31(6):515-8. PubMed ID: 10575572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesalazine as a maintenance treatment in Crohn's disease.
    Sutherland LR; Steinhart AH
    Gut; 1998 Jan; 42(1):143-4. PubMed ID: 9505902
    [No Abstract]   [Full Text] [Related]  

  • 31. Medical therapy to reduce postoperative Crohn's disease recurrence.
    Achkar JP; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1139-46. PubMed ID: 10811318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
    Uittenbogaart SB; Klemt-Kropp M
    Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of 5-aminosalicylates for the maintenance of remission in Crohn's disease.
    Akobeng AK
    Am J Gastroenterol; 2011 Oct; 106(10):1857; author reply 1857-8. PubMed ID: 21979212
    [No Abstract]   [Full Text] [Related]  

  • 34. Obstructing Crohn's disease of the duodenum: is surgery always mandatory?
    Karaoglu AO; Yukselen V
    Int J Clin Pract; 2004 Feb; 58(2):221-3. PubMed ID: 15055874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesalazine for the treatment of inflammatory bowel disease.
    Criscuoli V; Modesto I; Orlando A; Cottone M
    Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on the management of Crohn's disease.
    Buchner AM; Blonski W; Lichtenstein GR
    Curr Gastroenterol Rep; 2011 Oct; 13(5):465-74. PubMed ID: 21792543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-aminosalicylates to prevent relapse of Crohn's disease after surgery.
    Doherty G; Moss AC
    Am J Gastroenterol; 2012 Mar; 107(3):487; author reply 487-8. PubMed ID: 22388032
    [No Abstract]   [Full Text] [Related]  

  • 39. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.
    Cammà C; Giunta M; Rosselli M; Cottone M
    Gastroenterology; 1997 Nov; 113(5):1465-73. PubMed ID: 9352848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.